Stock AnalizRadNet, Inc. RDNT
Medical Specialities · data as of November 13, 2026
RadNet, Inc. (RDNT) is a healthcare company listed in the US with a market value of about $6.0B. In the twelve months to September 30, 2026 it had revenue of $2.4B and net income of -$22M, a net margin of -0.9%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 52.3, 5-year revenue growth of 14% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 79% below the current price.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Interest covered more than 5 times
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4B | $2.0B | $1.8B | $1.6B | $1.4B | $1.3B | $1.1B | $1.2B | $975M | $922M | $885M |
| Net income | -$22M | -$19M | $3M | $3M | $11M | $25M | -$15M | $15M | $32M | $53000 | $7M |
| Free cash flow | $115M | $86M | $45M | $44M | $27M | $12M | $140M | $30M | $45M | $81M | $32M |
| EPS (diluted) | $-0.29 | $-0.25 | $0.04 | $0.05 | $0.17 | $0.46 | $-0.29 | $0.29 | $0.66 | $0.00 | $0.15 |
| Net margin | -0.9% | -0.9% | 0.1% | 0.2% | 0.7% | 1.9% | -1.4% | 1.3% | 3.3% | 0.0% | 0.8% |
| ROIC | — | 1.1% | 3.4% | 3.6% | 2.0% | 3.8% | 2.1% | 4.0% | 3.7% | 5.5% | 3.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $96.57, 26% above the current price; targets range from $79.00 to $108.00; the consensus rating is “Strong buy”; expected EPS is $0.60 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is RadNet stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 79% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does RadNet pay a dividend?
Not currently.
Is RadNet a good stock to buy?
We do not give buy or sell advice. RadNet scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.